Impact Factor 4.716 | CiteScore 4.71
More on impact ›

General Commentary ARTICLE

Front. Immunol., 29 November 2019 | https://doi.org/10.3389/fimmu.2019.02792

Commentary: p31-43 Gliadin Peptide Forms Oligomers and Induces NLRP3 Inflammasome/Caspase 1- Dependent Mucosal Damage in Small Intestine

  • 1Biomolecular Simulations Group, Institut Pasteur de Montevideo, Montevideo, Uruguay
  • 2Instituto de Estudios Inmunológicos y Fisiopatológicos (UNLP-CONICET), Universidad Nacional de La Plata, La Plata, Argentina

A Commentary on
p31-43 Gliadin Peptide Forms Oligomers and Induces NLRP3 Inflammasome/Caspase 1- Dependent Mucosal Damage in Small Intestine

by Gómez Castro, M. F., Miculán, E., Herrera, M. G., Ruera, C., Perez, F., Prieto, E. D., et al. (2019). Front. Immunol. 10:31. doi: 10.3389/fimmu.2019.00031

In our recent publication p31-43 Gliadin Peptide Forms Oligomers and Induces NLRP3 Inflammasome/Caspase 1- Dependent Mucosal Damage in Small Intestine” (1) we showed by a combination of experimental and simulation techniques that the peptide p31-43 Gliadin has an intrinsic propensity to form oligomers, which trigger the NLRP3 inflammasome, resulting in intestinal inflammation and pathology. In particular, molecular simulations performed with the SIRAH force field (2), showed that isolated p31-43 peptides exhibit a broad conformational dynamic with some PPII component, mostly related to the presence of Pro36 and Pro42. Simulation of multiple replicas showed a spontaneous tendency to aggregation with a concomitant increase in the PPII content for Pro38 and Pro 39.

After our paper came out, an independent group published the NMR structure of p31-43 and its P36A and F37A mutants (3). This work presented apparently contrasting results based on NMR spectroscopy suggesting p31-43 Gliadin is mainly monomeric, but not discarding the presence of possible aggregated structures. As the peptide structures were deposited in the Protein Data Bank, we reanalyzed our molecular dynamics trajectory conducting a structural comparison between the conformations sampled in our simulations and those based on NMR. As it can be observed from Figure 1A, the matching observed between monomer simulations and experimental structures is outstanding. Moreover, the structural superposition between individual peptides within the aggregate and the experimental structures is also remarkable (Figure 1B). This provides support to the idea that “the monomers are in fast exchange with self-assembled structures” and that “the 3D models represent the secondary elements adopted also in the oligomeric forms” (3). Indeed, selected conformations from the simulations are indistinguishable from those coming from the experimental determination (Figure 1C).

FIGURE 1
www.frontiersin.org

Figure 1. Structural superposition of the best matching solution between NMR derived conformations and simulation of isolated peptides (A), and peptides within the 50-mer aggregate (B). On (C), the final structures obtained by molecular dynamics of each peptide forming the oligomer (Y-axis) are compared against all the conformers reported in the NMR family of structures (X-axis). The degree of structural similarity is reported as the root mean square deviation (RMSD) between the C-alpha carbons of simulated and NMR derived conformers. Small RMSD values (red-yellow) identify high structural similarity. Simulations of P36A and F37A showed the same degree of structural similarity (not shown).

Besides highlighting the capacity of our simulation method to characterize the conformational behavior of peptides (Figure 1), the remarkable agreement between simulations and experiments in the oligomeric case provides strong support to the hypothesis that the p31-43 Gliadin peptide suffers very minor conformational changes when passing from monomeric to oligomeric states. This further strengthens the idea that aggregates might work as reservoirs that protect p31-43 from degradation. Though p31-43 monomers are quite resistant to degradation, the self-assembly process extends the persistence of large aggregates with higher toxic potency, particularly when disruption of the normal physiology of internal vesicles (1) and release of danger signals are considered as driving events for inflammation and cell damage (4).

Author Contributions

EB, FC, and SP wrote the paper.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Gómez Castro MF, Miculán E, Herrera MG, Ruera C, Perez F, Prieto ED, et al. p31-43 Gliadin peptide forms oligomers and induces NLRP3 inflammasome/caspase 1- dependent mucosal damage in small intestine. Front Immunol. (2019) 10:31. doi: 10.3389/fimmu.2019.00031

CrossRef Full Text | Google Scholar

2. Machado MR, Barrera EE, Klein F, Sóñora M, Silva S, Pantano S. The SIRAH force field 2.0: Altius, Fortius, Citius. J Chem Theory Comput. (2019) 15:2719–33. doi: 10.1021/acs.jctc.9b00006

PubMed Abstract | CrossRef Full Text | Google Scholar

3. Calvanese L, Nanayakkara M, Aitoro R, Sanseverino M, Tornesello AL, Falcigno L, et al. Structural insights on P31-43, a gliadin peptide able to promote an innate but not an adaptive response in celiac disease. J Pept Sci. (2019) 25:e3161. doi: 10.1002/psc.3161

CrossRef Full Text | Google Scholar

4. Lania G, Nanayakkara M, Maglio M, Auricchio R, Porpora M, Conte M, et al. Constitutive alterations in vesicular trafficking increase the sensitivity of cells from celiac disease patients to gliadin. Commun Biol. (2019) 2:190. doi: 10.1038/s42003-019-0443-1

PubMed Abstract | CrossRef Full Text | Google Scholar

Keywords: coarse grained (CG), simulations, celiac disease, p31-43, gliadin peptides, sirah force field

Citation: Barrera E, Chirdo F and Pantano S (2019) Commentary: p31-43 Gliadin Peptide Forms Oligomers and Induces NLRP3 Inflammasome/Caspase 1- Dependent Mucosal Damage in Small Intestine. Front. Immunol. 10:2792. doi: 10.3389/fimmu.2019.02792

Received: 02 July 2019; Accepted: 14 November 2019;
Published: 29 November 2019.

Edited by:

Paul W. Bland, University of Gothenburg, Sweden

Reviewed by:

Anne Jarry, Institut National de la Santé et de la Recherche Médicale (INSERM), France

Copyright © 2019 Barrera, Chirdo and Pantano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Sergio Pantano, spantano@pasteur.edu.uy